Antimicrobial photodynamic therapy for the potential treatment of oral candida infection in HIV/AIDS Patients: A Scoping Review

Objectives: Evaluate the impact of antimicrobial photodynamic therapy (aPDT) using various photosensitizers on Candida colonies and clinical symptoms associated with oral candidiasis, a common oral manifestation in HIV/AIDS patients.
Methods: A scoping review was conducted in PubMed and ScienceDirect, following Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA). A literature search was conducted in electronic databases to identify relevant articles up to October 25, 2024.
Results After excluding articles, only three were eligible for review. Based on the findings, aPDT performed better in reducing the number of Candida and clinical signs in the oral mucosa of HIV/AIDS patients.
Conclusion: Antimicrobial photodynamic therapy (aPDT) treatment using methylene blue (MB), with or without Potassium iodide (KI), can reduce Candida colonies and clinical symptoms in HIV/AIDS patients, offering a potential alternative therapy to enhance their quality of life. Further research is needed to refine antimicrobial photodynamic therapy (aPDT) parameters for treating oral candidiasis in these patients.